RATIONALE: The mechanisms that underlie the pathogenesis of chronic rhinosinusitis without nasal polyps (CRSsNP), chronic rhinosinusitis with nasal polyps (CRSwNP), and aspirin-exacerbated respiratory disease (AERD) are not clear. OBJECTIVES: To first evaluate the inflammatory profiles of CRSsNP and CRSwNP tissues and then to investigate whether clinical differences observed between CRSwNP and AERD are in part secondary to differences in inflammatory mediator expression within nasal polyp (NP) tissues. METHODS: Expression levels of numerous inflammatory mediators were determined by quantitative real-time polymerase chain reaction, ELISA, and multiplex immunoassay. MEASUREMENTS AND MAIN RESULTS: CRSwNP NP had increased levels of type 2 mediators, including IL-5 (P < 0.001), IL-13 (P < 0.001), eotaxin-2 (P < 0.001), and monocyte chemoattractant protein (MCP)-4 (P < 0.01), compared with sinonasal tissue from subjects with CRSsNP and control subjects. Expression of IFN-γ messenger RNA or protein was low and not different among the chronic rhinosinusitis subtypes examined. Compared with CRSwNP, AERD NP had elevated protein levels of eosinophil cationic protein (ECP) (P < 0.001), granulocyte-macrophage colony-stimulating factor (GM-CSF) (P < 0.01), and MCP-1 (P = 0.01), as well as decreased gene expression of tissue plasminogen activator (tPA) (P = 0.02). Despite the higher eosinophilia in AERD, there was no associated increase in type 2 mediator protein levels observed. CONCLUSIONS: CRSwNP was characterized by a predominant type 2 inflammatory environment, whereas CRSsNP did not reflect a classic type 1 milieu, as has been suggested previously. AERD can be distinguished from CRSwNP by elevated ECP levels, but this enhanced eosinophilia is not associated with elevations in traditional type 2 inflammatory mediators associated with eosinophil proliferation and recruitment. However, other factors, including GM-CSF, MCP-1, and tPA, may be important contributors to AERD pathogenesis.
RATIONALE: The mechanisms that underlie the pathogenesis of chronic rhinosinusitis without nasal polyps (CRSsNP), chronic rhinosinusitis with nasal polyps (CRSwNP), and aspirin-exacerbated respiratory disease (AERD) are not clear. OBJECTIVES: To first evaluate the inflammatory profiles of CRSsNP and CRSwNP tissues and then to investigate whether clinical differences observed between CRSwNP and AERD are in part secondary to differences in inflammatory mediator expression within nasal polyp (NP) tissues. METHODS: Expression levels of numerous inflammatory mediators were determined by quantitative real-time polymerase chain reaction, ELISA, and multiplex immunoassay. MEASUREMENTS AND MAIN RESULTS: CRSwNP NP had increased levels of type 2 mediators, including IL-5 (P < 0.001), IL-13 (P < 0.001), eotaxin-2 (P < 0.001), and monocyte chemoattractant protein (MCP)-4 (P < 0.01), compared with sinonasal tissue from subjects with CRSsNP and control subjects. Expression of IFN-γ messenger RNA or protein was low and not different among the chronic rhinosinusitis subtypes examined. Compared with CRSwNP, AERD NP had elevated protein levels of eosinophil cationic protein (ECP) (P < 0.001), granulocyte-macrophage colony-stimulating factor (GM-CSF) (P < 0.01), and MCP-1 (P = 0.01), as well as decreased gene expression of tissue plasminogen activator (tPA) (P = 0.02). Despite the higher eosinophilia in AERD, there was no associated increase in type 2 mediator protein levels observed. CONCLUSIONS: CRSwNP was characterized by a predominant type 2 inflammatory environment, whereas CRSsNP did not reflect a classic type 1 milieu, as has been suggested previously. AERD can be distinguished from CRSwNP by elevated ECP levels, but this enhanced eosinophilia is not associated with elevations in traditional type 2 inflammatory mediators associated with eosinophil proliferation and recruitment. However, other factors, including GM-CSF, MCP-1, and tPA, may be important contributors to AERD pathogenesis.
Authors: Mahboobeh Mahdavinia; Roderick G Carter; Christopher J Ocampo; Whitney Stevens; Atsushi Kato; Bruce K Tan; Robert C Kern; David B Conley; Rakesh Chandra; Kathryn E Hulse; Lydia A Suh; James E Norton; Anju T Peters; Leslie C Grammer; Lawrence B Schwartz; Robert P Schleimer Journal: J Allergy Clin Immunol Date: 2014-03-15 Impact factor: 10.793
Authors: L A Beck; C Stellato; L D Beall; T J Schall; D Leopold; C A Bickel; F Baroody; B S Bochner; R P Schleimer Journal: J Allergy Clin Immunol Date: 1996-10 Impact factor: 10.793
Authors: Samuel L Oyer; Jennifer K Mulligan; Alkis J Psaltis; Oswaldo A Henriquez; Rodney J Schlosser Journal: Laryngoscope Date: 2013-08-06 Impact factor: 3.325
Authors: Sudarshan Seshadri; Mariel Rosati; David C Lin; Roderick G Carter; James E Norton; Andrew Wonho Choi; Lydia Suh; Atsushi Kato; Rakesh K Chandra; Kathleen E Harris; Hong Wei Chu; Anju T Peters; Bruce K Tan; David B Conley; Leslie C Grammer; Robert C Kern; Robert P Schleimer Journal: J Allergy Clin Immunol Date: 2013-07-26 Impact factor: 10.793
Authors: Jessica P Rajan; Nathan E Wineinger; Donald D Stevenson; Andrew A White Journal: J Allergy Clin Immunol Date: 2014-10-03 Impact factor: 10.793
Authors: Bruce K Tan; Aiko I Klingler; Julie A Poposki; Whitney W Stevens; Anju T Peters; Lydia A Suh; James Norton; Roderick G Carter; Kathryn E Hulse; Kathleen E Harris; Leslie C Grammer; Robert P Schleimer; Kevin C Welch; Stephanie S Smith; David B Conley; Robert C Kern; Atsushi Kato Journal: J Allergy Clin Immunol Date: 2016-09-14 Impact factor: 10.793
Authors: Yoshimasa Imoto; Atsushi Kato; Tetsuji Takabayashi; Whitney Stevens; James E Norton; Lydia A Suh; Roderick G Carter; Ava R Weibman; Kathryn E Hulse; Kathleen E Harris; Anju T Peters; Leslie C Grammer; Bruce K Tan; Kevin Welch; Stephanie Shintani-Smith; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer Journal: J Allergy Clin Immunol Date: 2019-09-25 Impact factor: 10.793
Authors: Ava R Weibman; Julia He Huang; Whitney W Stevens; Lydia A Suh; Caroline P E Price; Alcina K Lidder; David B Conley; Kevin C Welch; Stephanie Shintani-Smith; Anju T Peters; Leslie C Grammer; Atsushi Kato; Robert C Kern; Robert P Schleimer; Bruce K Tan Journal: Int Forum Allergy Rhinol Date: 2017-09-01 Impact factor: 3.858